Sensitivity of 18F-fluorodihydrotestosterone PET-CT to count statistics and reconstruction protocol in metastatic castration-resistant prostate cancer-Reference-Cited by-同舟云学术

Sensitivity of 18F-fluorodihydrotestosterone PET-CT to count statistics and reconstruction protocol in metastatic castration-resistant prostate cancer

Published:2019-07-30 Issue:1 Volume:9 Page:
ISSN:2191-219X
Container-title:EJNMMI Research
language:en
Short-container-title:EJNMMI Res

Author:

Cysouw Matthijs C. F.^ORCID,Kramer Gerbrand M.,Heijtel Dennis,Schuit Robert C.,Morris Michael J.,van den Eertwegh Alfons J. M.,Voortman Jens,Hoekstra Otto S.,Oprea-Lager Daniela E.,Boellaard Ronald

Funder

Movember Foundation

Publisher

Springer Science and Business Media LLC

Subject

Radiology Nuclear Medicine and imaging

Link

http://link.springer.com/content/pdf/10.1186/s13550-019-0531-8.pdf

Reference34 articles.

1. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev. 2004;25(2):276–308.

2. Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16(2):152–60.

3. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995–2005.